Nephrology

The HRB CRFG Nephrology research team successfully completed participation in the FIDELIO trial this year which was published in the NEJM in November 2020. The study demonstrated a delay in the progression of kidney disease with a novel agent in patients with diabetic Nephropathy. We continue involvement in the FIGARO trial which is another study of the same agent with cardiovascular outcomes. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease in Addition to Standard of Care

The Nephrology research team have also participated in research assessing US guidance of intravascular volume status in dialysis patients in recent years and have just embarked on participating in a new registry study of patients with polycystic kidney disease being treated with Tolvaptan.”

The principal investigator is Professor Donal Reddan.